

# Thrombosis in childhood ALL



*Gili Kenet*

*Professor, Hematology Faculty  
Tel Aviv University*

*Director– National Hemophilia Center & Thrombosis Institute*

*Sheba Medical Center  
Tel HaShomer, Israel*

# Case report


6 years old boy with ALL  
started chemotherapy 1 month ago.  
Central catheter difficulty of drawing  
blood

**What are the options? And how to  
proceed?**



# Incidence of venous thrombotic events per 100,000 according to age

Figure 1. Annual incidence of VTE among residents of Worcester MA 1986, by age and sex. (Reproduced by permission from Anderson FA, et al. *Arch Intern Med.* 1991;151:933-938.)



Among children neonates exhibit the highest risk for thrombosis

# Thrombotic Disorders

- Genetic

- Factor V Leiden mutation
- Protein C deficiency
- Protein S deficiency
- Antithrombin III deficiency
- prothrombin 20210 mutation

- Acquired

- Antiphospholipid antibodies
  - (Anti-Cardiolipin antibodies)
- Cancer
- Atherosclerosis
- Hyper-homocysteinemia
- Infection
- Stasis
- Injury

# Virchow's triad in cancer patients

## ▶ Endothelial damage

- *Shift to procoagulant endothelium*
- *Invasion of cancer cells into vessel wall*

## ▶ Stasis of blood


- *Frequent immobilization, surgery*
- *Compression of blood vessels by tumor*

## ▶ Changes in the blood constituents

- *Activation of clotting proteins and blood cells*



**Rudolf Virchow**  
1821–1902



## Thrombotic complications in childhood acute lymphoblastic leukemia: a meta-analysis of 17 prospective studies comprising 1752 pediatric patients

Vanessa Caruso, Licia Iacoviello, Augusto Di Castelnuovo, Sergio Storti, Guglielmo Mariani, Giovanni de Gaetano, and Maria Benedetta Donati

The risk of thrombosis in children with acute lymphoblastic leukemia (ALL) reportedly ranges between 1% and 37%. Epidemiologic studies have usually been hampered by small numbers, making accurate estimates of thrombosis risk in ALL patients very difficult. The aim of this study was to better estimate the frequency of this complication and to define how the disease, its treatment, and the host contribute to its occurrence. We made an attempt to combine and analyze all published data on the

association between pediatric ALL and thrombosis, by using a meta-analytic method. The rate of thrombosis in 1752 children from 17 prospective studies was 5.2% (95% CI: 4.2-6.4). The risk varies depending on several factors. Most of the events occurred during the induction phase of therapy. Lower doses of asparaginase (ASP) for long periods were associated with the highest incidence of thrombosis, as were anthracyclines and prednisone (instead of dexamethasone). The presence of central

lines and of thrombophilic genetic abnormalities also appeared to be frequently associated with thrombosis. In conclusion, the overall thrombotic risk in ALL children was significant, and the subgroup analysis was able to identify high-risk individuals, a finding that will hopefully guide future prospective studies aimed at decreasing this risk. (Blood. 2006;108:2216-2222)

© 2006 by The American Society of Hematology

## Thrombosis and acute lymphoblastic leukaemia

Jeanette H. Payne and Ajay J. Vora

Department of Paediatric Haematology, Sheffield Children's Hospital, Sheffield, UK

## A Prospective Cohort Study Determining the Prevalence of Thrombotic Events in Children with Acute Lymphoblastic Leukemia and a Central Venous Line Who are Treated with L-Asparaginase

*Results of the Prophylactic Antithrombin Replacement in Kids with Acute Lymphoblastic Leukemia Treated with Asparaginase (PARKAA) Study*

Lesley G. Mitchell, *M.Sc.*  
and the PARKAA Group

Population Health Sciences, The Hospital for Sick Children, Toronto, Ontario, Canada.

Presented in part at the meeting of the American Society of Hematology, New Orleans, Louisiana, December 4, 1999. Also presented in part at the International Congress on Thrombosis, Porto, Portugal, May 7, 2000.

Supported by a grant from the Canadian Institutes of Health Research (grant PA 14283) and by Bayer Inc.

L.G.M. is a research scholar of the Canadian Institutes of Health Research. M.A. and J.G. are a career investigators of the Heart and Stroke Foundation of Ontario.

Members of the Prophylactic Antithrombin Replacement in Kids with Acute Lymphoblastic Leukemia Treated with Asparaginase (PARKAA) group are: Maurice Andrew MD, Population Health Sciences, The Hospital for Sick Children, Toronto, Canada; Kim Hanna M.Sc, Bayer Inc., Toronto, Canada; Thomas Abramo MD, Hematology/Oncology, Emory University School of Medicine, Atlanta, USA; Jacqueline Halton MD, Hematology/Oncology, Children's Hospital of Eastern Ontario, Ottawa, Canada; Ron Anderson MD, Dept Hematology/Oncology, Alberta Children's Hospital, Calgary, Canada; Irene Chenick MD, Dept Hematology/Oncology, University Hospital, Syracuse, USA; Sunit Doshi MD, Dept Hematology/Oncology, W MacKenzie Health Sciences Centre, Edmonton, Canada; Donald Maloney MD, Dept Hematology/Oncology, Texas Children's Hospital, Houston, USA; Patricia McDougal MD, Hematology/Oncology, Children's Hospital of Western, London, Canada; John Wu MD, Hematology/Oncology, B.C. Children's Hospital, Vancouver, Canada; Gary Ts'ao

**BACKGROUND.** Thrombotic events (TEs) are serious secondary complications in children with acute lymphoblastic leukemia (ALL) who receive L-asparaginase (ASP) therapy; however, the prevalence of TEs has not been established. The primary objective of the Prophylactic Antithrombin Replacement in Kids with Acute Lymphoblastic Leukemia Treated with Asparaginase (PARKAA) Study was to determine the prevalence of TEs. The secondary objective was to detect any association of TEs with the presence of congenital or acquired prothrombotic disorders.

**METHODS.** Children with ALL were screened for TEs at the end of ASP treatment using bilateral venograms, ultrasound, magnetic resonance imaging, and echocardiography. Symptomatic TEs were confirmed by appropriate radiographic tests. All tests were read by a blinded central adjudication committee.

**RESULTS.** Twenty-two of 60 children had TEs, a prevalence of 36.7% (95% confidence interval, 24.4-48.8%). TEs were located in the intravenous system of the brain in 1 patient, the right atrium in 3 patients, and the upper central venous system in 19 patients. TEs detected by venography resulted in 1) 25-100% occlusion, with 1 in 3 patients showing occlusion of > 75% of the greatest vessel diameter, and 2) the presence of collaterals in 60% of patients, with 40% categorized as major. No children with TEs were positive for factor V Leiden or prothrombin gene 20210A, and four of eight children with antiphospholipid antibodies had a TE.

M.D., Hematology/Oncology, Stanford University School of Medicine, Palo Alto, USA; Peter Chai MD, Radiology, Hospital for Sick Children, Toronto, Canada; Gabrielle de Vaker, Neurology, Hospital for Sick Children, Toronto, Canada; Wyoung-Jin Lee MD, Cardiology, Hospital for Sick Children, Toronto, Canada; David Mikulis, Neurology, Toronto General Hospital, Toronto, Canada; Jeffrey Sinsberg MD, Medicine, McMaster University, Hamilton, Canada; Clifford Way MD, Cardiology, McMaster University, Hamilton, Canada.

The authors acknowledge and thank the study coordinators: Patsy Vogt, Monks Adams, Karen Blynske, Alex Blay, Tracy Cor, Elaine Dofard, Christine McDonald, Julie Nichols, Judy Power, Chris Tromblay, and Hanna Zahra.

The authors are all deeply saddened by the loss of their colleague and friend, Dr. Maurice Andrew, who passed away suddenly on August 26, 2001. Dr. Andrew was instrumental in the work reported here, and the authors respectfully dedicate this article to her memory.

Address for reprints: Lesley G. Mitchell, M.Sc., Population Health Sciences, Hospital For Sick Children, 555 University Avenue, Toronto, Ontario, Canada M5G 1X8; Fax: (416) 813-5075; E-mail: lesley.mitchell@sickkids.ca

Received February 22, 2002; revision received August 12, 2002; accepted August 15, 2002.

© 2003 American Cancer Society

# Epidemiology



- ▶ **Cancer is found in 20% of pediatric patients with VTE**
- ▶ The most common malignancy in children is ALL, therefore it has an important role and impact on the pathogenesis and occurrence of VTE in children.
- ▶ **The reported prevalence of symptomatic VTE in children with ALL ranges from 2–3% (retrospective BFM study) and 14% (prospective study),** however the prevalence of all reported cases including asymptomatic cases may range in some studies to up to 73%.
- ▶ **There is a high incidence of PTS in survivors of childhood ALL. A significant proportion of ALL survivors develop PTS, indicating previously undiagnosed DVT**




# VTE risk factors in paediatric ALL

- ▶ treatment with *Escherichia coli* asparaginase
- ▶ concomitant use of steroids
- ▶ presence of central venous lines
- ▶ thrombophilic genetic abnormalities

[Caruso et al 2006 ; Payne 2007 ; Mitchell 2010; Nowak-Gottl 2011]

# *Hemostatic changes in leukemia - pre-therapy*



Principe et al . Thrombosis in adult patients with acute leukemia.  
CurrOpinOncol 29 (2017) 448-454

# Post therapy: Steroids

- ▶ Increase production of pro-coagulant FXII, FXI, FIX, FX, FVIII, FVII, FV, FII and inhibitors of proteolysis (PAI-I, anti-plasmin)
  - ▶ Reduce fibrinolysis (tpa, plasminogen)
  - ▶ N- Gottl et al. demonstrated that dexamethasone may have some protective role vs prednisone in induction therapy
  - ▶ **Changes in protocols entail a different risk of thrombosis**
- 
- ▶ Athale et al. Evaluation for inherited and acquired prothrombotic defects predisposing to symptomatic thromboembolism in children with acute lymphoblastic leukemia: a protocol for a prospective, observational, cohort study, *BMC Cancer*. 2017 May 4;17(1):313
  - ▶ Nowak Gottl U et al; Thromboembolic events in children with ALL (BFM protocol): prednisone vs dexamethasone administration. *Blood*. 2003:

# L-asparaginase

- An increase in thrombotic events has been observed with the use of L-asp in a variety of chemotherapy protocols (Mitchell, *Semin Thromb Hemost*, 1995)

- Thrombosis is mainly venous with a predilection to the central nervous system

(Kieslich, *Pediatr Oncol*, 2003.

Alberts,  
*Leuk Lymphoma*, 1999)

## Increased Endogenous Thrombin Generation in Children With Acute Lymphoblastic Leukemia: Risk of Thrombotic Complications in L-Asparaginase-Induced Antithrombin III Deficiency

By L. Mitchell, D. Hasegawa, A. H. Janu, P. Vajta, and M. Andrew

Patients with acute lymphoblastic leukemia (ALL) are at an increased risk of thrombotic events. Pediatric endogenous thrombin levels indicate the human prothrombin activator complex (APC) is a major inhibitor of the human L-Asparaginase (ASP). We studied thrombin generation in 100 nonrelapsed children with ALL and 18 healthy age-matched controls by (1) plasma concentrations of prothrombin, (2) plasma inhibition of  $^{125}I$ -thrombin and (3) four biochemical markers of in vivo thrombin activation (thrombin generation by the fibrinolytic activator t-PA, t-PAI, plasminogen fragments 1 & 2 [F1,2], activation protein C [concentration to the inhibition of activator] [APC:AI], and protein C inhibitor [APC:PI]). Thrombotic events (stroke and disseminated intravascular coagulation) were more frequent in ASP therapy than in controls. We conclude that thrombin generation is increased in children with ALL and that thrombin generation is increased in children with ALL compared with age-matched controls. ASP therapy is used as part of combination chemotherapy, pro-

thrombin levels were measured, whereas plasma inhibition of  $^{125}I$ -thrombin decreased significantly because of a decrease in plasma concentrations of inhibition, most importantly APC. In addition, thrombin generation and ASP plasma concentrations of t-PAI and the capacity to inhibit  $^{125}I$ -thrombin increased in several children. Thrombin generation in vivo also differed from healthy controls. As generation, plasma concentrations of three of four markers of in vivo thrombin activity (F1,2, APC:AI, and not APC:PI) were increased in children with ALL. Plasma ASP alone rise contribution chemotherapy with or without ASP significantly altered values of these three markers. In summary, although the in vivo capacity to generate thrombin was preserved, the in vivo capacity to inhibit  $^{125}I$ -thrombin decreased after ASP therapy. Evidence for increased endogenous thrombin generation was demonstrated in children with ALL at generation and throughout treatment. We conclude that poor regulation of this thrombin may contribute to thrombotic complications in children with ALL.

© 1998 by The American Society of Hematology.

and is used aggressively in the circulation phase of the ALL protocol. ASP interferes with protein synthesis, thereby impairing the production of some coagulation proteins.

The ALL protocols have an intentional window at diagnosis, facilitating evaluation of the effect of a single chemotherapeutic agent on untreated lymphoblasts in vivo. For the ALL protocol 87002, the single drug was ASP. This provided an ideal opportunity to assess the effects of ASP on blood coagulation independent of previous or concurrent chemotherapy. In addition, blood coagulation was assessed in children before any induction and other combination chemotherapy with and without ASP.

The generation and inhibition of thrombin activation seem to be normal. Some of the markers of thrombin generation of thrombin have been reported and include release of plasminogen fragments 1 & 2 [F1,2] by prothrombinase, thrombin complexed to its main inhibitor, plasminogen, t-PAI, and the generation of activated protein C, an inhibitor of thrombin. The capacity to inhibit thrombin can also be accurately measured. We used these assays to assess thrombin regulation in children with ALL at diagnosis, after treatment with ASP alone, and after treatment with combination chemotherapy with or without ASP.

### MATERIALS AND METHODS

**Patients population.** The patient population was comprised of 36 consecutive patients with ALL, diagnosed at the Children's Hospital of Chicago, St. Louis, between March 1990 and July 1994. Their ages ranged from 2 to 13 years with a median age of 5 years. All children were diagnosed with ALL as previously published<sup>1</sup> and placed on the ALL protocol 87002.

**THE TREATMENT OF childhood acute lymphoblastic leukemia (ALL) has advanced to the extent that 5-year event-free survival (EFS) rates of approximately 80% have been achieved. The chemotherapy protocols for childhood ALL, developed at the Dana-Farber Cancer Institute (DFCI), Boston, MA, are currently among the most successful. Children with standard risk (SR) ALL, defined by age and white blood cell count, have an 80% chance of a 5-year EFS, and children with high risk (HR) disease, a 75% 5-year EFS.<sup>1</sup> The Children's Hospital of Chicago (University Medical Center, Hamilton, Ontario, Canada) has participated in the DFCI study group since 1985 and has achieved rates similar to the entire group.<sup>2</sup> The successful treatment of ALL has been achieved since 1985 and has involved therapy of varying severity and intensity. Extracranial disease has been largely eliminated. Extracranial disease is a very effective chemotherapeutic agent**

From the Department of Pediatrics, McMaster University, Hamilton, and the Department of Pathology, Queen's University, Kingston, Ontario, Canada.  
Submitted May 10, 1998; accepted September 9, 1998.  
Supported by a grant from the Canadian Red Cross Society. M.A. is a Career Scientist with the Health and Welfare Foundation of Canada. A.H.J. is a Career Research Professor of the Heart and Stroke Foundation of Ontario. Address reprint requests to M. Andrew, MD, McMaster University, Faculty of Health Sciences, Department of Pediatrics, Room 2023, 1200 Main St E, Hamilton, Ontario L8N 2Z5, Canada.  
The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked advertisement in accordance with IACR article 17 data rights to the copyright owner.  
© 1998 American Society of Hematology  
0885-0666/98/050505-06\$05.00/0

Table 1. Plasma Concentration of Coagulation Proteins

Test	Pretreatment at Diagnosis (n = 14)	After Treatment With ASP Only (n = 15)	Combination Therapy Without ASP (n = 15)	Combination Therapy With ASP* (n = 12)	Normal Controls (n = 14)
II ( $\mu\text{g/mL}$ )	0.94 $\pm$ 0.07	0.79 $\pm$ 0.05	1.19 $\pm$ 0.06†	1.22 $\pm$ 0.08†	0.88 $\pm$ 0.02
ATIII ( $\mu\text{g/mL}$ )	0.98 $\pm$ 0.03	0.58 $\pm$ 0.04†	0.95 $\pm$ 0.04	0.70 $\pm$ 0.06†	0.99 $\pm$ 0.03
$\text{t-PA}$ ( $\mu\text{g/mL}$ )	1.8 $\pm$ 0.12	1.57 $\pm$ 0.08	1.49 $\pm$ 0.1	1.60 $\pm$ 0.11	2.25 $\pm$ 0.3
HClII ( $\mu\text{g/mL}$ )	1.35 $\pm$ 0.13†	0.68 $\pm$ 0.06†	1.37 $\pm$ 0.13†	0.85 $\pm$ 0.10	0.97 $\pm$ 0.06
Protein C ( $\mu\text{g/mL}$ )	0.89 $\pm$ 0.07	0.61 $\pm$ 0.09†	1.30 $\pm$ 0.11	1.07 $\pm$ 0.1	0.9 $\pm$ 0.05
Total protein S ( $\mu\text{g/mL}$ )	0.96 $\pm$ 0.09	0.68 $\pm$ 0.04	1.11 $\pm$ 0.07†	1.03 $\pm$ 0.05†	0.78 $\pm$ 0.03
Free protein S ( $\mu\text{g/mL}$ )	0.28 $\pm$ 0.03†	0.24 $\pm$ 0.03†	0.47 $\pm$ 0.02	0.33 $\pm$ 0.03	0.41 $\pm$ 0.03

Data are presented as mean  $\pm$  one standard error of the mean.


\* Represents time in therapy that the patients are at risk for thrombotic events.

† Indicates a significant difference from healthy controls of at least  $P < .01$ .

# Asparaginase– MOA

- ▶ Decrease of natural anticoagulants such as anti–thrombin, protein C and S following which there is an increase in thrombin generation.
- ▶ Risk of thrombosis does not seem to be significantly affected by type of ASP utilized. However, **different commercial preparations exhibit various half life of ASP enzymes and may result in prolonged periods of hemostatic impairment**

# IRs of clinical thrombotic events in different subgroups of studies



equivalent dosages:


Erwinia

E. Coli A [Crasnitin]

E. Coli B [Kyowa, Japan]



A prospective cohort study determining the prevalence of thrombotic events in children with acute lymphoblastic leukemia and a central venous line who are treated with L-asparaginase



Cancer 2003; 97(2): 508-516

# More clinical data?

**MEDICAL HISTORY FORM**

Patient's name \_\_\_\_\_ DOB \_\_\_\_\_ Weight \_\_\_\_\_ Yes / No

**CURRENT SYMPTOMS**

Cough/Sputum > 3 weeks Yes / No  
Fever, unexplained Yes / No  
Weight loss / anorexia Yes / No  
Night sweats Yes / No  
Fatigue Yes / No

**MEDICAL HISTORY**

Asthma Yes / No  
Cancer Yes / No  
Depression Yes / No  
Epilepsy Yes / No  
Ear throat Yes / No  
Ear problems Yes / No  
Heart disease Yes / No  
Liver disease Yes / No

**FAMILY HISTORY**

Heart Disease Yes / No  
Cancer Yes / No  
Hypertension Yes / No

**ALLERGIES**

If yes, please specify  
Latex/Rubber/Eggs/Soybeans/Peanuts/Other \_\_\_\_\_

Please list all medications you are allergic to \_\_\_\_\_

Pressure Yes / No  
Diabetes Yes / No  
Cancer Yes / No  
Allergies Yes / No  
Mental problems Yes / No  
Other Yes / No

**SOCIAL HISTORY**

Do you smoke? \_\_\_\_\_  
Do you drink? \_\_\_\_\_  
Do you live? \_\_\_\_\_

wiseGEEK

# Clinical presentation – *Location of thrombosis*

- Most thrombotic events are of a venous origin
- most common location for thrombosis was CNS in 50% of cases, of which the majority were **cerebral venous thrombosis**.
- **upper limb DVT** associated with CVL comprised 27.5% cases.
- The rest : PE=1%  
Right atrium (1%) ,  
superficial (2.2%)




Fig. 1. Anatomical distribution of symptomatic TE in children with ALL; DVT=deep venous thrombosis. Over 50% of TEs are reported in venous locations like CNS, right atrium and pulmonary thromboembolism; DVT=deep venous thrombosis;

*U.H. Athale, A.K.C. Chan / Thrombosis Research 111 (2003) 125–131*


CNS-TE = central nervous system thromboembolism.

# *Arterial thrombosis*



- ▶ Acute ischemic stroke (AIS) in the context of childhood ALL has been reported
- ▶ In large retrospective study looking at ischemic stroke among children treated for ALL, of a total of 2,318 ALL patients, 11 symptomatic ischemic strokes occurred in 11 patients (0.47%)
- ▶ **Moyamoya** syndrome occurs in increased frequency in survivors of childhood ALL. This may be attributed to treatment with cranial irradiation

your  
next  
step





► What are the options? And how to proceed?



a



## Pediatric Blood & Cancer

RESEARCH ARTICLE

### Need for tissue plasminogen activator for central venous catheter dysfunction is significantly associated with thrombosis in pediatric cancer patients

Jessica MacLean, Tamara MacDonald, Carol Digout, Nadine Smith, Krista Rigby, Ketan Kulkarni

First published: 14 March 2018

<https://doi.org/10.1002/pbc.27015>

### Abstract

#### 1 Background



# Treatment of malfunctioning CVAD

- ▶ Malposition → remove.
- ▶ Fibrin sheath → Urokinase
- ▶ Thrombus → Anticoagulation (ACT):

In children with CVAD in place who have a VTE, if CVAD no longer required or nonfunctioning—  
> remove, after at least 3–5 days ACT.

If CVAD still required and functioning, should remain in situ, and patient given ACT



CHEST

Supplement

ANTITHROMBOTIC THERAPY AND PREVENTION OF THROMBOSIS, 9TH ED. ACCP GUIDELINES

**Antithrombotic Therapy in Neonates  
and Children**

**Antithrombotic Therapy and Prevention of Thrombosis,  
9th ed: American College of Chest Physicians  
Evidence-Based Clinical Practice Guidelines**

*Paul Monagle, MBBS, MD, FCCP; Anthony K. C. Chan, MBBS,*


*Neil A. Goldenberg, MD, PhD; Barbara N. Howard, MD,*

*Janus M. Journeay, MD, MSc; Ulrike Noack-Groß, MD; and Sam K. Viscy, PhD*

# Role of Thrombophilia? Should we test?




# Ped VTE– Statistics (%IT)



controls (healthy)

patients

## Relative risk of thrombotic events in ALL children with at least one prothrombotic genetic defect



- ▶ **Asp** therapy may exacerbate inherited deficiency of **AT**, **PC** and **PS** even in heterozygous patients. **FV Leiden** may exacerbate the suppression of **PC** and **PS** as a result of **ASP** therapy.
- ▶ **Steroids** increase **prothrombin** levels, thus, **PTM** may render patients to even higher levels and increased risk of **DVT**.
- ▶ **MTHFR C677T** homozygosity in presence of folic acid deficiency may lead to endothelial activation due to increased Homocysteine levels– **MTX**.



- 1) Treat with LMWH
- 2) Check for thrombophilia?
- 3) Consider antithrombotic prophylaxis for high risk patients/situations
- 4) Neither FFP nor routine use of AT recommended in order to reduce thrombosis risk

BJH, Jan 2018: BSH guidelines : management of thrombosis in pediatric malignancy



# Pediatric Thrombosis– Treatment



CHEST

Supplement

ANTITHROMBOTIC THERAPY AND PREVENTION OF THROMBOSIS, 9TH ED: ACCP GUIDELINES

## Antithrombotic Therapy in Neonates and Children

Antithrombotic Therapy and Prevention of Thrombosis,  
9th ed: American College of Chest Physicians  
Evidence-Based Clinical Practice Guidelines

*Paul Monagle, MBBS, MD, FCCP; Anthony K. C. Chan, MBBS;  
Neil A. Goldenberg, MD, PhD; Rebecca N. Ichord, MD;  
Janna M. Journeycake, MD, MScS; Ulrike Nowak-Göttl, MD; and Sara K. Vesely, PhD*

CHEST / 141 / 2 / FEBRUARY, 2012 SUPPLEMENT



# Treatment

- ▶ 3 month of anticoagulation for DVT associated with cancer followed by 6 month of therapy if no clot resolution has occurred.
- ▶ Prophylaxis should be continued as long as any of the following risk factors exist: active cancer, CVL and chemotherapy.
- ▶ It has been previously recommended that patients that have suffered from DVT when re-introduced to ASP should receive anticoagulant prophylaxis prior to administration and for 48 hours post ASP exposure

# Anti Coagulant Treatment

**Low molecular weight heparin** is the most commonly used treatment for DVT in children.

There are no evidence based studies of VTE treatment in children with hematological malignancies.....

Anti Xa should be monitored !



# Should ACT prophylaxis be applied to children with ALL?



	BFM	COALL	FRALLE
<b>Scoring system A</b>			
Induction starting day 8			
DEXA or PDN 40 mg/m <sup>2</sup>	+ (0.5 points)	—	+ (0.5 points)
PDN 60 mg/m <sup>2</sup> and ASP 5000–6000 IU/m <sup>2</sup>	++ (1 point)		
Maximum score	1.0	0	0.5
<b>Scoring system B</b>			
CVL, Broviac/Port	+ (1 point)	+ (1 point)	+ (1 point)
Genetics			
Thrombophilia (n = 1)	+ (1 point)	+ (1 point)	+ (1 point)
Thrombophilia (> 1)	+ (2 points)	+ (2 points)	+ (2 points)
Maximum score	3	3	3
Total score, minimum	0.5	0	0.5
Scoring systems A and B, maximum score	4.0	3.0	3.5


**Pediatric ALL population:**

Pilot cohort- 465 of 552 / Validation cohort- 339 of 347

# ***Pediatric VTE: Primary prophylaxis - Suggested prophylaxis score***

<b>Points</b>		<b>Risk factor</b>
1		ALL
1	positive family history/single thrombophilia	
<b>2</b>	<u>or</u> <b>combined thrombophilia</b> /APS	
1		central venous line
<hr/>		
$\Sigma$		<b>Risk score</b>
$\leq 1$		low risk
2		medium risk
<b><math>\geq 3</math></b>		<b>high risk</b>

*\*E. coli B ASP 5000/m<sup>2</sup> x8; prednisone 60 mg/m<sup>2</sup>*



# Consider VTE prophylaxis in ALL [high risk VTE patients]


- ▶ risk score  $\geq 3$
- ▶ enoxaparin 1 mg/kg/24h
  - prophylaxis start: days 8–12 (induction therapy)



platelet count  $< 20.000/\mu\text{l}$ : stop



# AT Treatment- PARKAA



- ▶ PARKAA was an open, randomised, controlled study in children with ALL being treated with ASP.
- ▶ Children were randomised to receive **antithrombin infusions** or no antithrombin treatment. All thrombotic events were confirmed using bilateral venography, ultrasound, echocardiography and MRI.
- ▶ **The incidence of thrombosis in patients treated with antithrombin was 28% (95% CI 10–46%), compared to 37% (95% CI 24–49%) in the non treated arm.** Two minor bleeds occurred in patients in the treated arm, but were not considered to be related to antithrombin. No significant differences were seen in plasma markers by the treatment group.
- ▶ In conclusion, treatment with antithrombin concentrate shows a trend to efficacy and safety. In contrast, there was no difference in surrogate markers for thrombosis. Carefully designed clinical trials are needed to test the efficacy and safety of antithrombin in this population

# Alternative anticoagulants

- ▶ Unfractionated **heparin** has the limitations of continuous administration, increased bleeding tendency however it is easily reversed.
- ▶ **Warfarin**, the only currently approved oral anticoagulant has a narrow therapeutic index, is affected by drug interactions and dietary changes that render it difficult for use in pediatric cancer patients.

	Discovered	Adult use	Ped Use
Heparin	1916	1937	1954
Warfarin	1929	1954	1976
LMWH	1970	1980	1990
Fondaparinux	1985	2001	2004

Bartolozzi G, Guazzelli C. [Two cases of septic thrombosis of the cavernous sinus cured by antibiotics and **heparin**.] Riv Clin Pediatr. 1954; Carpentieri U, Nghiem QX, Harris LC. Clinical experience with an **oral anticoagulant** in children. Arch Dis Child.1976; Massicotte P, Adams M, Mazinotto V, Brooker LA, Andrew M. **Low-molecular-weight heparin** in pediatric patients with thrombotic disease: a dose finding study. J Pediatr.1996; Young G, Nugent DJ. Use of argatroban and **fondaparinux** in a child with heparin-induced thrombocytopenia. Pediatr Blood Cancer. 2004;42:S542.

# DOAC

- ▶ Direct oral anticoagulants (DOAC) have become widely used in adult patients with DVT.
- ▶ However, their use in active cancer associated DVT is still limited
- ▶ Currently DOAC are not approved for children and are only administered within clinical studies

# Take home messages: Pediatric ALL thrombosis

- ▶ Epidemiology varies with study type
- ▶ Etiology: multifactorial
- ▶ Thrombophilia should not be routinely screened
- ▶ Different protocols yield variable risks
- ▶ Insufficient evidence to support replacement
- ▶ LMWH is the only drug for ACT
- ▶ Prophylaxis—individually tailored



# Thanks!

Albisetti M, Bonduel M,  
Brandao L, Chalmers L,  
Chan A, Goldenberg NA,  
Heller C, Holzhauser S,  
Journeycake J, Male C,  
Mollinari AC, Manco-  
Johnson M, Mitchel L,  
Monagle P, van Ommen  
CH, Raffini L, Ravel Vilks  
S, Simioni P, Young G,  
Nowak-Göttl U

